85639-55-0 Usage
Uses
Used in Pharmaceutical Industry:
(5alpha,17beta)-3-methylandrost-2-en-17-ol is used as a therapeutic agent for conditions such as hypogonadism, a medical condition in which the body produces little or no sex hormones, leading to impaired development or maintenance of secondary sexual characteristics and reproductive function in men. (5alpha,17beta)-3-methylandrost-2-en-17-ol helps in restoring the hormonal balance and alleviating the symptoms associated with hypogonadism.
Additionally, (5alpha,17beta)-3-methylandrost-2-en-17-ol is utilized in the treatment of certain types of breast cancer, particularly in postmenopausal women. Its androgenic properties help in managing the hormonal imbalances that contribute to the progression of the disease.
Used in Sports and Fitness Industry:
(5alpha,17beta)-3-methylandrost-2-en-17-ol is also used as a performance-enhancing drug due to its anabolic effects on muscle growth and bone density. Athletes and bodybuilders may use (5alpha,17beta)-3-methylandrost-2-en-17-ol to improve their physical performance, increase muscle mass, and enhance recovery times. However, it is essential to note that the use of such substances for performance enhancement may be prohibited in professional sports and can lead to adverse health effects if not used under medical supervision.
Check Digit Verification of cas no
The CAS Registry Mumber 85639-55-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,5,6,3 and 9 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 85639-55:
(7*8)+(6*5)+(5*6)+(4*3)+(3*9)+(2*5)+(1*5)=170
170 % 10 = 0
So 85639-55-0 is a valid CAS Registry Number.
85639-55-0Relevant academic research and scientific papers
Mono- and bisquaternary ammonium derivatives of 2β,16β-di-amino-5α-androstane derivatives and pharmaceutical preparations containing same
-
, (2008/06/13)
This invention relates to novel mono- and bisquaternary ammonium derivatives of 5α-androstanes having the formula: STR1 wherein: R1 =H or alkyl (1-4 C); R2 and R3 each are alkyl (1-4 C) or form together with the N-atom a piperidino, pyrrolidino or morpholino group; R4 =O or H(βOR5) and R5 =H or acyl derived from an organic carboxylic acid having 1-18, preferably 1-6 carbon atoms; the quaternarizing group being a saturated or unsaturated aliphatic hydrocarbon group having 1-4 carbon atoms the anion being halide; and acid addition salts of the monoquaternary compounds; and to pharmaceutical preparations containing one or more of said androstane compounds as active constituent. The compounds according to the invention are non-depolarizing neuromuscular blocking agents having very quick onset and recovery characteristics, a short duration of action and a favorable dissociation between muscle blocking and vagal blocking effects.
